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Alzheimer’s disease (AD) is generally defined as the aberrant production of β-amyloid
protein (Aβ) and hyperphosphorylated tau protein, which are deposited in β-amyloid
plaques (APs) and neurofibrillary tangles (NFTs), respectively. Decreased levels of
brain-derived neurotrophic factor (BDNF) have been detected in patients with AD
compared to control subjects. However, the underlying molecular mechanisms driving
the downregulation of the BDNF remain unknown. Therefore, we explored the
mechanisms underlying the regulation of BDNF in the neurons of APP/PS1 transgenic
(Tg) mice, an AD experimental model. Using the APP/PS1 Tg mice, we found that
BDNF expression was markedly downregualted at the age of 3- and 9-month-old. After
cerebroventricular injection (i.c.v) of Aβ1−42 oligomers into the mice, BDNF was also
found to be decreased, which demonstrated the critical roles of the Aβ1−42 oligomers in
regulating the expression of BDNF. In neuronal culture, peroxisome proliferators-activated
receptor γ coactivator 1α (PGC-1α) and fibronectin type III domain-containing 5
(FNDC5) were found to be downregulated by treatment with the Aβ1−42 oligomers. In
addition, overexpression of either PGC-1α or FNDC5 reversed the suppressive effects
of the Aβ1−42 oligomers on the expression of BDNF in neuroblastoma 2a (n2a) cells.
More importantly, elevating the levels of PGC-1α, FNDC5 or BDNF in the n2a cells
counteracted the effects of the Aβ1−42 oligomers on neuronal apoptosis. Additionally,
intranasal administration BDNF in the APP/PS1 Tg mice decreased the Aβ deposition
and reduced the cognitive decline of the mice.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by the pathological
production of β-amyloid protein (Aβ) and hyperphosphorylation
of tau in β-amyloid plaques (APs) or neurofibrillary tangles
(NFTs) (Bloom, 2014). Since Aβ accumulation multiple
affects multiple biological functions, such as oxidative stress,
neuroinflammation, neurotoxicity, autophagy and apoptosis
(Yankner, 1996), the components of APs received a great amount
of attention in prior works. For example, APs are essentially
composed of Aβ1−42 (Glenner and Wong, 1984) and Aβ23−35
(Kubo et al., 2002; Gruden et al., 2007). As a consequence,
different lengths of Aβ fragments greatly impair the normal
physiological functions of the brain.
Brain derived neurotrophic factor (BDNF) has been identified
as a versatile and multifunctional growth factor implicated in
the control of a wide spectrum of adaptive processes in both the
developing and adult brain, which range from the modulation of
synaptic connectivity and excitation in neurodegeneration (Park
and Poo, 2013). In patients with AD, the precursor form of BDNF
and mature BDNF or its mRNA are decreased in the parietal
cortex and hippocampus in the early stage of the disease (Phillips
et al., 1991; Holsinger et al., 2000; Michalski and Fahnestock,
2003; Peng et al., 2005). In addition, serum levels of BDNF
are also correlated with the severity of dementia (Laske et al.,
2007). Interestingly, individuals with the Val66Met mutation in
BDNF displays a decreased volume of specific brain regions and
impaired learning ability (Egan et al., 2003). Blocking BDNF
signaling with anti-TrkB antibodies induces cognitive decline in
exercise animal models (Vaynman et al., 2006). For these reasons,
BDNF has been suggested to control the aggregation of tau
protein in NFTs (Murer et al., 1999). However, the roles of BDNF
in Aβ production and deposition remain to be determined,
especially the underlying mechanisms.
Recently, peroxisome proliferator-activated receptor γ
coactivator 1α (PGC-1α) and fibronectin type III domain
containing 5 (FNDC5) were previously shown to be responsible
for regulating the expression of BDNF in mice (Wrann et al.,
2013). PGC-1α was initially identified as a beneficial factor
that was induced in skeletal muscle by exercise (Finck and
Kelly, 2006). A subsequent study revealed the important role of
PGC-1α in the inhibition of the neurodegeneration (Ma et al.,
2010). PGC-1α has been suggested to exert neuroprotective
effects against MPTP-induced Parkinson’s disease (St-Pierre
et al., 2006). In addition, PGC-1α also negatively regulates
N-methyl-D-aspartate (NMDA) receptor activities, which results
in reduction of excessive excitotoxicity in rat cortical neurons
(Cheng et al., 2012). FNDC5 was identified as a PGC-1α-
dependent myokine (Bostrom et al., 2012), that is expressed in
the brain (Dun et al., 2013). In addition, a previous study showed
that FNDC5 is located downstream of PGC-1α to modulate
BDNF regulation in mice (Wrann et al., 2013).
Although these investigations have provided fragments
of information about the potential connections between
FNDC5/PGC-1α and BDNF, their potential contributions
to AD still remain unknown. Therefore, we aimed to
reveal the mechanisms of BDNF downregulation during
the course of AD development and progression. In
addition, the effects of BDNF on neuronal apoptosis,
Aβ deposition and learning ability were further
addressed.
MATERIALS AND METHODS
Reagents
Aβ1−42 was synthesized by Qiangyao Biotechnology (Shanghai,
China). BDNF was obtained from Sigma-Aldrich Corp (St.
Louis, MO, USA). Antibodies specific for BDNF, PGC-1α,
and FNDC5 were obtained from Abcam (Shanghai, China).
Antibodies against Aβ (Stock #2454) and β-actin were purchased
from Cell Signaling Technology, Inc. (Danvers, MA, USA). Of
note, the Aβ antibody specifically reacts with human Aβ. PGC-
1α or FNDC5 cDNA plasmids were obtained from Origene
Technologies (Rockville, MD, USA) and subcloned into the
pCMV6-XL vector. All reagents for the qRT-PCR and SDS-
PAGE experiments were purchased from Bio-Rad Laboratories.
All other reagents are from Invitrogen (Carlsbad, CA, USA)
unless otherwise specified.
Cell Culture
Mouse neuro-2a (n2a) cells were grown (37◦C and 5% CO2)
on 6-cm tissue culture dishes (106 cells per dish) in DMEM
supplemented with 10% FBS medium. To enhance the efficacy
of transfection (Son et al., 2000), the cells were transfected with
cDNA constructs of PGC-1α and FNDC5 in serum-free medium
using lipofectamine 2,000, and the cells were maintained in
serum-free medium for an additional 12 h before incubation with
the Aβ1−42 oligomers.
Transgenic Mice and Treatments
The wild-type (WT) and APP/PS1 [B6C3-Tg (APPswe,
PSEN1dE9) 85Dbo/J (Stock Number: 004462)] Tg mice were
obtained from The Jackson laboratory (Bar Harbor, ME, USA).
Genotyping was performed at 3–4 weeks after birth. The mice
were housed in a controlled environment under a standard
room temperature, relative humidity and 12-h light/dark cycle
with free access to food and water. The general health and body
weight of the animals were monitored every day. The mouse
brains from the different groups were collected under anesthesia
and perfusion.
Aβ1−42 Oligomers Preparation
The methods for preparing Aβ1−42 oligomers has been described
previously (Pan et al., 2011). In brief, freeze-drying Aβ1−42
protein was initially monomerized by dissolution it to a final
concentration of 1 µg/µl in 100% hexafluoroisopropanal (HFIP)
and the solution was aliquoted in sterile eppendorf tubes. HFIP
was then evaporated under vacuum and the peptide was stored at
−20◦Cbefore reconstituent. For preparing Aβ1−42 oligomers, the
peptide was initially resuspended in dimethylsulfoxide (DMSO)
to 20 µg/µl with water bath ultrasonication for 10 min and the
solution was then diluted to a final concentration of 0.2 µg/µl in
phenol red-free F-12 media, and incubated at 4◦C for 24 h.
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Real-Time PCR
Real-Time PCR assays were performed with the MiniOpticon
Real-Time PCR detection system (Bio-Rad) using total RNA
and the GoTaq 1-step Real-Time PCR kit with SYBR Green
(Promega) and the appropriate primers. The reaction mixtures
were incubated at 50◦C for 15 min and then 97◦C for 5
min. Then, 35 PCR cycles were performed with the following
temperature profiles: 97◦C for 15 s, 58◦C for 30 s, 68◦C for 1 min,
and 77◦C for 1min. Data were collected at the final step (77◦C for
1 min) to prevent the inclusion of any fluorescence from primer
dimers. The GenBank accession number and forward and reverse
primers are as follows: mouse BDNF (NM_007540) F-TGA
GCAAAGCCGAACTTCTC, R-TCACCTGGTGGAACATTGT
G; PGC-1α (NM_008904) F-TGATGTGAATGACTTGGATAC
AGACA, R-GCTCATTGTTGTACTGGTTGGATATG; FNDC5
(NM_027402) F-ATGAAGGAGATGGGGAGGAA, R-GCGGC
AGAAGAGAGCTATAACA, and GAPDH (NM_001289726) F-
ACTCCACTCACGGCAAATTC, R-GGAGATGATGACCCTT
TTGG. The gene expression values were normalized to those
of GAPDH. Of note, the control group was always set as 1 and
the experimental groups were compared to the control groups as
previously described (Roberts et al., 2011).
Western Blots
The tissues or cells were lysed in radio-immune precipitation
assay buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, and 0.1% SDS) containing a
protease inhibitor cocktail (Pierce Chemical Company, Shanghai,
China). The protein content of the cell lysates was determined
using a bicinchoninic acid (BCA) protein assay reagent (Pierce
Chemical Company, Shanghai, China). The total cell lysates
(4µg) were subjected to SDS-PAGE, transferred to a membrane,
and probed with a panel of specific antibodies. Each membrane
was only probed with one antibody. β-actin was used as a loading
control. All western blots were performed at least in triplicate
using a different cell preparation each time.
Intracerebroventricular Injection
Aβ or vehicle (PBS) were intracerebroventricularly injected (i.c.v)
into C57BL/6mice. Briefly, stereotaxic injections were conducted
at the following coordinates from the bregma: mediolateral:−1.0
mm; anteroposterior: −0.22mm; and dorsoventral: −2.8 mm.
Following the injections, each mouse recovered spontaneously
on a heated pad. The reliability of the injection sites was validated
by injecting trypan blue dye (Invitrogen) into separate cohorts of
mice and observing staining in the cerebral ventricles. 24 h after
the injection, the mouse brains were harvested after anesthesia
and perfusion.
Immunohistochemistry
Mouse brains were collected from the WT or APP/PS1 Tg mice
and fixed with 4% paraformaldehyde. Serial sections (10 µM
thick) were cut using a cryostat (Leica, CM1850, Germany). The
slides were first rehydrated in a graded series of ethanol and
submerged in 3% hydrogen peroxide to eliminate endogenous
peroxidase activity. The levels of BDNF and Aβ were determined
using an immunohistochemical staining kit with antibodies
specific for BDNF (1:200 dilution in PB solution) and Aβ
(1:200 dilution in PB solution), following the manufacturer’s
instructions (Invitrogen).
Viability Assay
Neuronal viability was determined by an MTT assay with minor
modifications. In brief, n2a cells were incubated with an Ab in the
absence or presence of BDNF. After the treatments, Tiler 96 R©
Aqueous One Solution (20 µl) was added to the corresponding
wells and the cells were further incubated for 4 h. The optical
density was measured by a microplate reader (Bio-Rad, Bio-Rad
Laboratories, Inc., Hercules, California, USA) at a wavelength of
490 nm.
Flow Cytometry
Annexin V-FITC/PI double staining was used to detect the
apoptosis of n2a and SH-SY5Y cells. In detail, the cells were
collected with an enzyme-free cell dissociation buffer and washed
twice with cold PBS (−) before centrifugation at 2,500 rpm for 5
min (Thermo Fisher Scientific Inc., Waltham, MA, USA). The
cell pellets were then resuspended in 500 µl binding solution
with 5 µl annexin-V-fluorescein isothiocyanate and 5 µl of
propidium iodide before the analysis with a FACS Calibur flow
cytometer (Becton, Dickinson and Company, Franklin Lakes,
New Jersey, USA).
Morris Water Maze
The mice were trained and tested in a Morris water maze. In
brief, the mice were pretrained in a circular water maze with a
visible platform for 2 days. The platform was then submerged
inside the maze, with the deck 0.5 cm below the surface of the
water for the following experiments. Milk was added to the water
to hide the platform from sight. The mice were placed inside
the maze to swim freely until they found the hidden platform.
The whole experiment took place over 7 days. For the first 6
days, the mice were placed in the maze with a maximum of 60 s
to find the platform. The learning sessions were repeated with
4 trials each day, and an interval of 1 h between each session.
The spatial learning scores (the latency period necessary to find
and climb onto the hidden platform and the length of the path
to the platform) were recorded. On the last day, the platform
was removed, and the times that the mice passed through the
memorized region were recorded for a period of 2 min (120
s). Finally, the recorded data were analyzed with a statistical
program (ZH0065; Zhenghua Bioequipment, Yuanyang City,
Henan, China).
Animal Committee
All animals were handled according to the guidelines of the Care
and Use of Medical Laboratory Animals (Ministry of Health,
Peoples Republic of China, 1994), and all experimental protocols
were approved by the Laboratory Ethics Committees of the Navy
General Hospital, China.
Statistical Analysis
All data are presented as the means ± S.E. of at least three
independent experiments. The statistical significance of the
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differences between the means was determined with Student’s
t-test or one-way ANOVA, as appropriate.
RESULTS
BDNF Is Downregulated in APP/PS1 Tg
Mice, and Aβ1−42 Oligomers Can Decrease
the Expression of BDNF in the C57BL/6
Mice
Since previous studies have shown that BDNF is associated with
neuroprotective effects (Kitiyanant et al., 2012; Wang et al.,
2015), we first determined the expression levels of BDNF in
APP/PS1 Tg mice at 3 months of age. As shown in Figure 1A,
BDNF immunostaining was evident in the cerebral cortex and
hippocampus of 3-month-old C57BL/6 mice, and the positive
staining was reduced in 3-month-old APP/PS1 Tg mice. To
further confirm this finding, we examined the mRNA and
protein levels of BDNF in the APP/PS1 Tg mice. In agreement
with the immunostaining data, the mRNA and protein levels
of BDNF were downregulated in both the cerebral cortex and
hippocampus of the mice (Figure 1B and Supplemental Figure
1A). To reveal a possible reason for the downregulation of
BDNF, we injected Aβ1−42 oligomers (i.c.v) into 3-month-
old C57BL/6 mice. The results demonstrated that the Aβ1−42
oligomer injection (i.c.v) significantly suppressed the expression
FIGURE 1 | The expression of BDNF was downregulated in APP/PS1 Tg mice and Aβ1−42 oligomer injection decreased the expression of BDNF in
C57BL/6 mice. (A,B) The brains of the 3-month-old APP/PS1 Tg mice were collected after anesthesia and perfusion (n = 8). (C,D) In select experiments, the
Aβ1−42 oligomers (1 ng/5 µl) or vehicle (PBS) was injected (i.c.v) into the ventricles of the 3-month-old C57BL/6 mice (n = 8). (A,C) The immunoreactivity of BDNF
was determined by IHC with a BDNF-specific antibody before the analysis with microscopy. (B,D) The mRNA and protein levels of BDNF were determined by
qRT-PCR and western blots, respectively. GAPDH and β-actin served as the internal controls. The data represent the means ± S. E. of all the experiments. *p < 0.05
compared with WT or vehicle-treated controls.
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of BDNF in 3-month-old C57BL/6 mice (Figure 1C). Similar
to these immunostaining results, the western blot and real-
time PCR results also revealed the inhibitory effects of the
Aβ1−42 oligomers on the expression of BDNF (Figure 1D and
Supplemental Figure 1B). Consistent with these observations,
our data revealed that BDNF expression is downregulated in
APP/PS1 Tg mice, and BDNF expression is markedly decreased
in C57BL/6J mice injected with exogenous Aβ1−42 oligomers,
which supports a critical roles of Aβ1−42 oligomers in suppressing
the expression of BDNF during the course of AD development
and progression.
Aβ1−42 Oligomers Decreased the
Expression of BDNF through a PGC-1α- or
FNDC5-Dependent Mechanisms
We next sought to elucidate the mechanisms of BDNF regulation
in the APP/PS1 Tg mice. Since a previous study suggested that
PGC-1α or FNDC5 are responsible for BDNF regulation (Wrann
et al., 2013), we first evaluated the effects of Aβ oligomers on
the expression of PGC-1α and FNDC5. To this end, n2a cells
were treated with Aβ oligomers for 24 h. Treatment of the n2a
cells with Aβ oligomers decreased the expression of PGC-1α
and FNDC5 in the n2a cells (Figures 2A,B and Supplemental
Figure 1C). To further elucidate the potential roles of PGC-
1α and FNDC5 in regulating the expression of BDNF, we
transfected the n2a cells with cDNA constructs of PGC-1α
and FNDC5. The efficacy of transfection was confirmed by
western blots and real-time PCR. The results demonstrated that
PGC-1α and FNDC5 cDNA transfection significantly increased
the mRNA and protein expression of corresponding genes
(Figures 2C,D and Supplemental Figure 1D). Overexpression of
the PGC-1α and FNDC5markedly reversed the inhibitory effects
of Aβ1−42 oligomers on the mRNA and protein expression of
BDNF in the n2a cells (Figure 2E and Supplemental Figure 1E).
Based on these findings, our findings demonstrated that Aβ1−42
suppressed the expression of BDNF through a PGC-1α- and
FNDC5-dependent mechanism.
Elevating the Levels of PGC-1α, FNDC5
and BDNF Alleviates the Apoptotic Effects
of Aβ1−42 Oligomers on Neurons
Since the Aβ1−42 oligomers are critical for suppressing the
expression of BDNF in a PGC-1α- and FNDC5-dependent
manner, we were prompted to elucidate the biological roles of
BDNF in neurons. Therefore, the n2a cells were transfected
with cDNA constructs of PGC-1α and FNDC5 before the
treatment with the Aβ1−42 oligomers. Using an MTT assay,
we found that the Aβ oligomers clearly suppressed neuronal
viability (Figure 3A). More interestingly, the PGC-1α and
FNDC5 overexpression significantly reduced the negative effects
of the Aβ1−42 oligomers on neuronal viability (Figure 3A). To
determine the mechanism of the observed neuronal death, the
n2a cells were double stained with PI and annexin V after the
indicated treatment. With flow cytometry, we found that the
Aβ1−42 oligomers clearly induced neuronal apoptosis, which was
FIGURE 2 | The Aβ1−42 oligomers suppressed the expression of BDNF
through a PGC-1α- and FNDC5-dependent mechanism. (A,B) The n2a
cells were treated with Aβ oligomers (1 ng/ml) for 48 h. (C,D) In select
experiments, the n2a cells were transfected with either PGC-1α or FNDC5
cDNA for 48 h. (E) In separate experiments, the n2a cells were transfected
with either PGC-1α or FNDC5 cDNA before the treatment with Aβ oligomers
for 48 h. The mRNA and protein levels of BDNF, PGC-1α and FNDC5 were
determined by qRT-PCR and western blots, respectively. GAPDH and β-actin
served as the internal controls. The data represent the means ± S.E. of three
times experiments. *p < 0.05 compared with vehicle-treated or
vector-transfected controls. #p < 0.05 compared with Aβ-treated alone.
reversed by the transfection with the PGC-1α and FNDC5 cDNA
constructs (Figure 3B).
Due to the ability of PGC-1α and FNDC5 to modulate
the expression of BDNF, we further determined the roles of
BDNF in neuronal survival. To this end, we treated the n2a
cells with the Aβ1−42 oligomers in the absence or presence
of BDNF for the indicated times. The results demonstrated
that BDNF treatment partially reversed the effects of the
Aβ1−42 oligomers on neuronal death (Figure 3C). Similarly,
BDNF also attenuated the apoptosis of the Aβ1−42 oligomer-
stimulated n2a cells (Figure 3D). These observations clearly
demonstrated that elevating the levels of PGC-1α, FNDC5
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FIGURE 3 | Elevating the levels of PGC-1α, FNDC5 and BDNF partially protected neurons from Aβ1−42 oligomer-induced apoptosis. (A,B) The neurons
were incubated with Aβ (1 ng/ml) in the absence or presence of transfection with either PGC-1α or FNDC5 cDNA. (C,D) In select experiments, the n2a cells were
incubated with Aβ (1 ng/ml) in the absence or presence of BDNF (1 ng/ml). (A,C) The viability of neurons in different groups was determined by an MTT assay. (B,D)
The apoptosis of neurons was determined by flow cytometry after staining with PI and annexin V. The data represent the means ± S. E. of three times experiments. *p
< 0.05 compared with vehicle-treated or vector-transfected controls. #p < 0.05 compared with Aβ-treated alone.
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and BDNF ameliorates the effects of the Aβ1−42 oligomers on
neuronal apoptosis.
BDNF Treatment Suppresses the
Deposition of Aβ and Reduces the
Cognitive Decline of the APP/PS1 Tg Mice
Since BDNF counteracted the effects of the Aβ1−42 oligomers
on neuronal apoptosis, we next sought to determine the roles of
BDNF in the aggregation of Aβ and the cognitive decline of the
APP/PS1 Tg mice. The results demonstrated that the deposition
and aggregation of Aβ was highly induced in the APP/PS1 Tg
mice and Aβ was deposited in the APs in the 9-month-old
APP/PS1 Tg mice (Figure 4A). As BDNF is downregulated in 9-
month-old APP/PS1 Tg mice (Supplemental Figure 2), we added
back BDNF to the mice in order to determine the roles of BDNF
in the deposition of Aβ. Of note, the BDNF treatment partially
decreases the number of APs in the 9-month-old APP/PS1 Tg
FIGURE 4 | BDNF treatment inhibits the deposition of Aβ and alleviates the cognitive decline of the APP/PS1 Tg mice. The APP/PS1 Tg mice at 3 months
of age received BDNF (1 ng/5 µl/d) intranasally for 6 months (n = 7). (A) The number of APs was determined by IHC using an Aβ-specific antibody. (B) The learning
ability of the different groups of mice was determined by the Morris maze test. *p < 0.05 compared with vehicle-treated controls. #p < 0.05 compared with
Aβ-treated alone.
Frontiers in Aging Neuroscience | www.frontiersin.org 7 March 2017 | Volume 9 | Article 65
Xia et al. The Roles of Aβ in Suppressing the Expression of BDNF
mice (Figure 4A). These observations demonstrate BDNF is
beneficial for decreasing the deposition of Aβ in the APP/PS1 Tg
mice.
Since we observed that the BDNF decreases the number of
APs, we next investigated the relationship between brain BDNF
levels and memory deficits in the APP/PS1 Tg mice. To this
end, we assessed both spatial learning and memory abilities
with the Morris water maze task. The results demonstrated that
the untreated APP/PS1 Tg mice exhibited unequivocal learning
deficits in the Morris water maze at 9 months of age (Figure 4B).
The BDNF treatment improved the cognitive decline of the
APP/PS1 Tg mice (Figure 4B). When we performed a probe
test at 24 h after the last training trial, the untreated APP/PS1
Tg mice showed no preference for the target quadrant, which
indicated significant memory impairment, whereas the BDNF-
treated APP/PS1 Tg mice performed better than the non-treated
APP/PS1 Tg mice (Figure 4B). These results clearly revealed that
BDNF expression was downregulated in the APP/PS1 Tg mice
and that the Aβ1−42 oligomers played critical roles in decreasing
the expression of BDNF through a PGC-1α- and FNDC5-
dependent mechanism. Reciprocally, elevating the levels of PGC-
1α, FNDC5 and BDNF partially ameliorated the negative effects
of the Aβ1−42 oligomers on neuronal survival. Additionally, the
BDNF treatment clearly decreased the deposition of Aβ and
reduced the cognitive decline of the APP/PS1 Tg mice.
DISCUSSION
AD is characterized by the aberrant production of Aβ and
hyperphosphorylated tau, which aggregate in APs and NFTs,
respectively (Bloom, 2014). Recently, BDNF expression was
found to be downregulated in conjunction with the development
and progression of AD (Phillips et al., 1991; Holsinger et al., 2000;
Michalski and Fahnestock, 2003; Peng et al., 2005). However,
the underlying mechanisms of the relationship between BDNF
and AD remained unknown. Therefore, we sought to determine
the mechanisms of BDNF downregulation, and the beneficial
effects of BDNF on AD. Indeed, the Aβ1−42 oligomers have the
ability to inhibit the expression of BDNF through a PGC-1α-
and FNDC5-dependent mechanism. Reciprocally, treatment of
neurons with exogenous BDNF prevents the Aβ1−42 oligomers-
induced neuronal apoptosis. Additionally, the BDNF treatment
has the ability to alleviate the aggregation of Aβ and reduce the
cognitive decline of the APP/PS1 Tg mice (Figure 5).
BDNF expression is tightly regulated in physiological
conditions. In AD patients, BDNF expression was shown to
be downregulated in conjunction with the development and
progression of AD (Phillips et al., 1991; Holsinger et al., 2000;
Michalski and Fahnestock, 2003; Peng et al., 2005). In agreement
with these prior works, we found that the expression of BDNF
was downregulated in the APP/PS1 Tg mice. More interestingly,
we further identified the Aβ1−42 oligomers as the key factors
that inhibit the expression of BDNF in the APP/PS1 Tg mice.
Consistent with our observations, Lattanzio et al. (2016) reported
that Aβ25−35 has ability to suppress the expression of BDNF in
SH-SY5Y cells. Furthermore, Aβ oligomers are able to reduce the
expression of BDNF in the APOE4 Tg mice (Sen et al., 2015).
FIGURE 5 | Signaling events involved in BDNF regulation during the
course of AD development and the critical roles of BDNF in inhibiting
the apoptosis of neurons, Aβ deposition and cognitive decline of the
APP/PS1 Tg mice. BDNF expression was downregulated in the APP/PS1 Tg
mice, and the Aβ1−42 oligomers are responsible for decreasing the expression
of BDNF through a PGC-1α- and FNDC5-dependent mechanism.
Reciprocally, elevating the levels of PGC-1α, FNDC5 and BDNF alleviated the
effects of the Aβ1−42 oligomers on neuronal apoptosis. More importantly,
BDNF treatment decreased the deposition of Aβ and reduced the cognitive
decline of APP/PS1 Tg mice.
Thus, the aggregation of Aβ may be critical for downregulating
the expression of BDNF during the course of AD development
and progression.
In addition to our finding that the Aβ1−42 oligomers exert
suppressive effects on the expression of BDNF, we found that
PGC-1α and FNDC5 are involved in regulating the expression of
BDNF. In agreement with our observation, PGC-1α and FNDC5
were demonstrated to be critical for the synthesis of BDNF in
the brains of mice (Wrann et al., 2013). Although the current
findings are quite limited, PGC-1α has been suggested to play
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an important role in the brain. For example, a lack of PGC-1α
in the brain is associated with neurodegeneration (Lin et al.,
2004; Ma et al., 2010). Outside of the context of AD, PGC-1α
has also been reported to maintain neuronal dendritic spines
(Cheng et al., 2012). Apart from PGC-1α, FNDC5 has been
reported to trigger the differentiation of PC12 cells into neuronal
cells (Ostadsharif et al., 2011). Knockdown of FNDC5 expression
in neuronal precursors impairs their development into mature
neurons, which suggests a beneficial role for FNDC5 in neurons
(Hashemi et al., 2013). Therefore, we added to the previous body
research and determined that the Aβ1−42 oligomers suppress the
expression of BDNF through a PGC-1α- and FNDC5-dependent
mechanism.
The Aβ1−42 oligomers are neurotoxic, so it is easier to
demonstrate the neuroprotective effects of BDNF on neurons
via disrupting the aggregation of APs. Indeed, BDNF exerted
protective effects on neurons and blocked Aβ1−42-induced
apoptosis. Consistent with our observations, Aβ exhibited dose-
dependent toxicity in cortical neurons (Geci et al., 2007). In
addition, BDNF has been reported to protect neurons from
cellular damage (Lindvall et al., 1994). In animal models, BDNF
was suggested to protect neurons from tau-induced impairment
(Jiao et al., 2016). Furthermore, BDNF was reported to rescue
neurogenesis in Aβ-injured neurons (Kitiyanant et al., 2012;
Wang et al., 2015). These observations support our data showing
that BDNF prevents neuronal death via inhibiting apoptosis in
the Aβ1−42 oligomers-treated neurons.
Based on this finding, mutating BDNF or blocking its receptor,
TrkB, were shown to clearly impair learning ability in the brains
of animal models (Egan et al., 2003; Vaynman et al., 2006). The
levels of BDNF in serum are also associated with the severity of
dementia (Laske et al., 2007). In a model of AD, upregulation
of BDNF ameliorates the cognitive decline of rats (Li et al.,
2016). Consistent with this observation, a series of investigations
have demonstrated that the cognitive decline of the APP/PS1 or
3XTg-AD mice was improved once the expression of BDNF was
upregulated by different stimuli (Corona et al., 2012; Xiang et al.,
2014). In our study, BDNF played pivotal roles in suppressing the
deposition of Aβ and reducing cognitive decline of the APP/PS1
Tg mice.
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